Navigation Links
FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream”
Date:7/8/2010

Fight SMA partners with the Gwendolyn Strong Foundation on a fundraising campaign for spinal muscular atrophy gene therapy.

(PRWEB) July 8, 2010 -- Richmond-based FightSMA announced today a new fundraising campaign for SMA gene therapy, “Realizing the Dream.” FightSMA is collaborating with the Santa Barbara –based Gwendolyn Strong Foundation, to form a bi-coastal partnership with a common goal: to bring SMA gene therapy to clinical trial.    “Ten years ago, it would have been unheard of to say scientists were approaching a treatment or cure for spinal muscular atrophy (SMA),” said FightSMA President Martha Slay. “Today, the dream is being realized in some of the most prestigious labs across the country. Never before has there been such promise for SMA gene therapy.” Beginning now and for the next three years, families and groups in the SMA community will raise funds to build a safe foundation, deliver genes to an SMA model, and produce adequate vector (gene delivery) supply. These efforts will support Dr. Brian Kaspar of Nationwide Children’s Hospital and The Ohio State University and other collaborating scientists. FightSMA, working with the Gwendolyn Strong Foundation, a funding source for critical SMA science and awareness initiatives, invites the SMA community to make a decade-old dream come true. “Our SMA gene therapy program at Nationwide Children’s Hospital and the Ohio State University continues to show great promise for treating SMA patients,” said Dr. Kaspar. FightSMA’s objective for the balance of 2010 is to complete funding for Phase One, and for Year-One of Phase-Two of the research program. “The first objective is to build a solid foundation of safety and to eliminate toxicity,” said Dr. Chris Lorson, FightSMA Science Director.” Additionally, FightSMA plans to raise another $250,000 to fund the first year of Phase Two (Delivery & Efficacy). The “Realizing the Dream” program will be accomplished through a series of campaigns. Completing these two Phases will bring SMA gene therapy significantly closer to clinical trial.    FightSMA has been instrumental in helping to develop a gene therapy strategy to cure spinal muscular atrophy (SMA), including oligonucleotides and gene replacement vectors. The strides that SMA researchers have made in the gene therapy arena have provided insights into a range of genetic disorders, including other neurodegenerative disease (ALS/Lou Gehrig's disease, myotonic dystrophy, Huntington disease) and other diseases such as Duchenne muscular dystrophy. For more information on the FightSMA – Gwendolyn Strong Foundation partnership and “Realizing the Dream” campaign, visit FightSMA announced today a new fundraising campaign for SMA gene therapy, “Realizing the Dream.”  FightSMA is collaborating with the Santa Barbara –based Gwendolyn Strong Foundation, to form a bi-coastal partnership with a common goal: to bring SMA gene therapy to clinical trial.
 
 “Ten years ago, it would have been unheard of to say scientists were approaching a treatment or cure for spinal muscular atrophy (SMA),” said FightSMA President Martha Slay.  “Today, the dream is being realized in some of the most prestigious labs across the country.  Never before has there been such promise for SMA gene therapy.”
 
Beginning now and for the next three years, families and groups in the SMA community will raise funds to build a safe foundation, deliver genes to an SMA model, and produce adequate vector (gene delivery) supply.   These efforts will support Dr. Brian Kaspar of Nationwide Children’s Hospital and The Ohio State University and other collaborating scientists. 

FightSMA, working with the Gwendolyn Strong Foundation, a funding source for critical SMA science and awareness initiatives, invites the SMA community to make a decade-old dream come true. “Our SMA gene therapy program at Nationwide Children’s Hospital and the Ohio State University continues to show great promise for treating SMA patients,” said Dr. Kaspar.
 
FightSMA’s objective for the balance of 2010 is to complete funding for Phase One, and for Year-One of Phase-Two of the research program. 

“The first objective is to build a solid foundation of safety and to eliminate toxicity,” said Dr. Chris Lorson, FightSMA Science Director.”

Additionally, FightSMA plans to raise another $250,000 to fund the first year of Phase Two (Delivery & Efficacy).  The “Realizing the Dream” program will be accomplished through a series of campaigns.  Completing these two Phases will bring SMA gene therapy significantly closer to clinical trial. 
 
FightSMA has been instrumental in helping to develop a gene therapy strategy to cure spinal muscular atrophy (SMA), including oligonucleotides and gene replacement vectors. The strides that SMA researchers have made in the gene therapy arena have provided insights into a range of genetic disorders, including other neurodegenerative disease (ALS/Lou Gehrig's disease, myotonic dystrophy, Huntington disease) and other diseases such as Duchenne muscular dystrophy.

For more information on the FightSMA – Gwendolyn Strong Foundation partnership and “Realizing the Dream” campaign, visit www.fighsma.org or call 804-515-0080.

FightSMA was created to strategically accelerate the search for a treatment and cure for spinal muscular atrophy (SMA), the number-one inherited cause of infant death. The organization pursues this objective by raising awareness and funding for SMA research For more information, please visit http://fightsma.org.
 
###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4232554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Hooper Holmes Heritage Labs Division Launches New Home Diabetes Test
2. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
3. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
4. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
5. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
6. ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
7. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
8. Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
9. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream” 
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):